logo-loader

Futura Medical begins recruitment for MED2002 safety trial

Published: 14:58 30 Nov 2017 GMT

James Barder, chief executive of Futura Medical plc (LON:FUM), tells Proactive they've begun recruitment for a pharmacokinetic study of their lead product, MED2002.

It's a prelude to starting phase III trials of the breakthrough gel for erectile dysfunction.

Data from 40 men will determine the doses used in the final-stage clinical assessment, which will kick off as “soon as practicable” after the current programme.

Futura Medical marks pivotal year with first meaningful revenue from Eroxon...

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company as it rolled out its innovative sexual health product, Eroxon, designed to treat erectile dysfunction. The over-the-counter availability of Eroxon distinguishes...

on 7/2/24